Day TwoWednesday, 20 May 2026 - CET (Central European Time, GMT+01:00)

The US represents the world's largest medtech market, but Nordic companies face unique challenges when expanding across the Atlantic; from FDA regulatory differences and reimbursement complexities to cultural sales approaches and talent acquisition. This panel features Nordic medtech leaders, investors, and experts who understand the operational realities of building American businesses while maintaining Nordic roots.

• Building your business model in the US

• Reimbursement, IP and regulatory considerations for expansion

• Building teams in the US, hiring, compensation, and cultural integration challenges

• The importance of accessing US venture capital

The Nordic region hosts major medtech corporations alongside a thriving startup ecosystem, creating unique partnership opportunities. But navigating these relationships requires compromise between agile startups and established corporations. This panel takes learnings from startup founders, investors and corporate venture leaders who understand the Nordic partnership landscape.

• Different partnership models and knowing what is best for your business

• Defining win-win outcomes and success metrics for both parties

• Engaging early and building relationships with relevant strategics

The medtech IPO market is showing signs of recovery after years of dormancy, with 2025 delivering notable public offerings and renewed investor appetite. But timing remains critical as companies balance market conditions, regulatory landscapes, and investor expectations. This panel of experts discuss the current IPO environment, what's driving the recovery, and strategic considerations for medtech companies planning public offerings in the next 18 months.

• Reviewing the IPO landscape

• The relevance of European public markets against the US

• Revenue thresholds, profitability paths and growth metrics for going public

• IPO vs M&A vs continued private growth

Patient engagement is evolving from a tokenistic "checklist" approach to a model that values patients as true partners in healthcare innovation. Medtech companies must recognize the importance of equitable patient involvement, including fair compensation for their time and expertise. By embracing patient-led initiatives and innovative communication formats, medtechs can drive meaningful collaboration and improve healthcare outcomes. Our panel of investors and operators discuss how patient engagement has shaped thier companies and investment thesis.

• Transitioning from checklist approaches to true patient partnerships in medtech innovation.
• Addressing funding and compensation challenges to ensure equitable patient involvement.
• Leveraging patient-led projects and innovative communication formats to drive engagement.
• How investors view patient engagement when reviewing an investment opportunity